BioVersys Works to Bring Antibiotic Resistance to an End

Abstract

BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to overcome antibiotic resistance. The co-founders share their view on what makes successful scientists pursue a career as start-up entrepreneurs rather than a classic academic career. They describe the history and milestones of their company, and how their everyday work differs from that of peers in an academic or industrial research setting.

Keywords

• Antibiotic resistance
• Bioversys
• Life science start-up
• Nosocomial infections
• Tric
• Tuberculosis